GeminIQ Website Logo

Viewing AMRX free

Subscribe for full history, 50+ metrics, screener, watchlist...

Amneal Pharmaceuticals, Inc.

AMRX

Companies in Pharmaceutical Preparations

Amneal Pharmaceuticals, Inc. (AMRX) — SEC Financial Statements & Analysis

Amneal Pharmaceuticals, Inc. (AMRX) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Common Class A
000-313313001309001
Common Class B
000000000000
Related Party
8518957853754776-2210166961416675
Nonrelated Party
8518957853754776-2210166961416675
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
19828220172591117444479287109
Restricted Cash And Cash Equivalents At Carrying V…
429351078465895
Inventory Net
642606615609601612596576571581576551
Prepaid Expense And Other Assets Current
10398102858981828287839182
Assets Current
1,7981,9111,8381,5851,5101,5881,5131,4851,3801,3781,4561,422
Property Plant And Equipment Net
445443435440427425431425440448452459
Goodwill
594595596597597597598599599599599599
Intangible Assets Net Excluding Goodwill
5355635886506897327808208598909831,015
Operating Lease Right Of Use Asset
-54---42---43--
Other Assets Noncurrent
555839454560367774568993
Assets
3,5403,6783,6003,4233,3653,5013,4613,5103,4563,4733,6873,701
Liabilities And Stockhold…
Liabilities Current
Litigation Reserve Current
114341424432303130777777
Lines Of Credit Current
-0029029010014017917917976120
Long Term Debt Current
677313222422522534343130
Liabilities Current
7288828621,1071,0761,1301,0951,114834847761777
Long Term Debt Noncurrent
2,5662,5652,5672,1462,1542,1622,1702,1782,3782,3862,5422,549
Other Notes Payable
------0042414141
Litigation Reserve Noncurrent
7072747473858585850--
Liabilities Noncurrent
2,7722,7912,7802,3622,3492,4162,3992,4002,6392,5652,7352,741
Temporary Equity Carrying Amount Including Portion…
867768667365605347413732
Stockholders Equity Inclu…
Preferred Stock Value
000000000000
Additional Paid In Capital
536572563555546560553546539539715708
Retained Earnings Accumulated Deficit
-473-535-570-572-595-607-576-576-582-490-392-401
Accumulated Other Comprehensive Income Loss Net Of…
-112-111-106-97-86-66-74-30-24-3248
Stockholders Equity
-46-71-109-112-132-109-93-57-6420331151
Minority Interest
-1-1-0-0-0-0-0-000-177-167
Liabilities And Stockholders Equity
3,5403,6783,6003,4233,3653,5013,4613,5103,4563,4733,6873,701
Preferred Stock Par Or Stated Value Per Share
0.010.010.010.010.010.010.010.010.010.010.010.01
Preferred Stock Shares Authorized
222222222222
Preferred Stock Shares Issued
000000000000

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-4.01%25.58%----------
20251.39%12.60%11.63%16.44%18.76%28.50%7.38%11.06%14.84%-14.34%0.72%-13.61%
20241.37%-3.64%12.90%13.20%7.06%9.80%-8.65%-15.46%-10.70%-0.12%-15.11%-12.34%
202337.10%66.67%69.89%-5.80%-5.80%-15.85%12.29%46.27%32.29%13.54%25.42%23.93%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
2.47
2.17
2.13
1.43
1.40
1.41
1.38
1.33
1.65
1.63
1.91
1.83
Quick Ratio
1.45
1.37
1.30
0.80
0.76
0.79
0.76
0.74
0.87
0.84
1.04
1.02
Working Capital
1.07B
1.03B
976.37M
477.56M
434.63M
458.04M
418.09M
371.13M
545.66M
531.27M
695.47M
644.44M
Leverage & Debt
Debt to Equity
-76.14
-51.48
-33.27
-30.95
-26.01
-32.38
-37.40
-61.12
-54.50
170.47
10.57
23.33
Interest Coverage TTM
1.83
1.63
1.45
1.51
1.44
0.96
0.73
0.72
0.70
0.97
1.14
1.03
Debt Ratio
0.99
1.00
1.01
1.01
1.02
1.01
1.01
1.00
1.00
0.98
0.95
0.95
Efficiency & Turnover
Asset Turnover TTM
0.88
0.84
0.83
0.82
0.83
0.80
0.75
0.72
0.70
0.66
0.63
0.60
Per Share Metrics
Diluted EPS TTM
0.55
0.39
0.19
0.22
0.13
-0.24
-0.44
-0.44
-0.43
-0.14
-0.36
-0.41
Free Cash Flow Per Share TTM
0.76
0.86
0.84
0.90
0.81
0.79
0.86
0.68
0.52
0.86
0.46
0.48
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Margin Metrics
Gross Profit Margin TTM
38.66%
36.88%
36.76%
37.67%
36.69%
36.52%
35.34%
35.04%
35.28%
34.28%
35.46%
34.94%
Operating Profit Margin TTM
14.30%
13.05%
12.19%
13.19%
12.73%
8.92%
7.00%
6.72%
6.38%
8.54%
9.48%
8.43%
Net Profit Margin TTM
5.95%
4.24%
2.13%
2.52%
1.50%
-2.64%
-5.12%
-5.36%
-5.35%
-2.04%
-4.80%
-5.49%
Growth Metrics
Net Revenue Growth (1Y)
7.62%
8.05%
9.50%
9.81%
13.42%
16.73%
12.32%
12.37%
9.82%
8.20%
11.54%
8.92%
Net Income Growth (1Y)
327.78%
-273.17%
-145.61%
-151.67%
-131.77%
51.63%
19.91%
9.85%
-48.60%
-80.88%
-21.65%
-15.16%
EPS Growth (1Y)
321.05%
-270.75%
-144.96%
-150.91%
-131.38%
72.87%
19.44%
9.27%
-49.11%
-83.61%
-23.08%
-16.67%
Valuation Metrics
P/E TTM
21.66
30.86
50.23
35.25
61.50
-33.12
-18.77
-14.09
-13.96
-43.89
-11.37
-7.51
P/B
-85.45
-55.36
-28.73
-22.64
-19.80
-22.35
-27.57
-34.14
-29.22
106.86
3.93
6.32
P/S TTM
1.29
1.31
1.07
0.89
0.92
0.88
0.96
0.76
0.75
0.89
0.55
0.41
Market Cap
3.93B
3.95B
3.14B
2.54B
2.61B
2.45B
2.58B
1.96B
1.86B
2.14B
1.30B
953.18M
Enterprise Value
6.30B
6.55B
5.52B
4.93B
5.01B
4.81B
5.03B
4.50B
4.41B
4.64B
3.85B
3.54B
Calculated Values
Free Cash Flow TTM
240.77M
269.93M
264.31M
282.99M
251.03M
243.18M
266.21M
211.11M
158.73M
302.36M
141.65M
146.39M
Net Debt
2.37B
2.60B
2.37B
2.40B
2.41B
2.37B
2.46B
2.54B
2.54B
2.50B
2.55B
2.59B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-05-11Sale
Owner: Autor, Deborah M.
Title: -
Shares: 34,819
Price/Share: $12.94
Value: $450,557.86
Shares Owned: 93,660
Relationship: Director
Ownership: Direct
2025-11-17Sale
Owner: Nark, Ted C
Title: -
Shares: 50,000
Price/Share: $11.72
Value: $586,000.00
Shares Owned: 291,029
Relationship: Director
Ownership: Direct
2025-11-12Sale
Owner: Shah, Nikita
Title: Executive Vice President
Shares: 131,856
Price/Share: $11.92
Value: $1,571,723.52
Shares Owned: 146,403
Relationship: Officer
Ownership: Direct
2025-08-27Sale
Owner: Kiely, John
Title: -
Shares: 32,000
Price/Share: $9.23
Value: $295,360.00
Shares Owned: 225,433
Relationship: Director
Ownership: Direct
2025-08-25Sale
Owner: Shah, Nikita
Title: Executive Vice President
Shares: 6,340
Price/Share: $9.50
Value: $60,230.00
Shares Owned: 146,403
Relationship: Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
48.88%
Inst. Shares: 154,483,525
Shares Outstanding: 316,023,000
2025-12-31
47.92%
Inst. Shares: 150,150,166
Shares Outstanding: 313,367,000
2025-09-30
46.27%
Inst. Shares: 145,350,982
Shares Outstanding: 314,168,000
2025-06-30
43.09%
Inst. Shares: 135,203,138
Shares Outstanding: 313,739,000
2025-03-31
41.65%
Inst. Shares: 129,569,332
Shares Outstanding: 311,054,000

Research Faster.
Invest Smarter.

Amneal Pharmaceuticals, Inc. (AMRX) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.